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Background: The PLATO trial showed that ticagrelor, a reversible oral P2Y12 receptor inhibitor, reduced the risk of cardiovascular events in 
patients with acute coronary syndromes (ACS) compared to clopidogrel but was associated with increased incidence of dyspnea. This substudy 
assessed whether ticagrelor affects pulmonary function in ACS patients.
Methods: 199 patients enrolled in the PLATO trial and receiving randomised treatment with ticagrelor 90 mg bid (n=101) or clopidogrel 75 
mg qd (n=98) took part in the pulmonary substudy. Patients with advanced lung disease, congestive heart failure or recent CABG were excluded. 
Pulse oximetry (SpO2), spirometry (FEV1, FVC, FEF25-75; pre and 20 min post inhaled beta agonist), lung volumes (TLC, FRC, RV) and diffusion 
capacity (DLCOSB) were performed after receiving study medication for 30-40d. Tests were then repeated both within 10d prior to and 20-30d after 
discontinuation of study medication.
Results: 6 ticagrelor-treated patients and 8 clopidogrel-treated patients experienced dyspnea during the study. After a mean treatment of 31d, 
there were no differences between the groups for any of the pulmonary function parameters (Table). At the end of treatment (mean 211d) and after 
discontinuation of medication (mean 32d post last dose), there was also no evidence of change in pulmonary function in either group.
Conclusions: Ticagrelor in ACS patients is not associated with any detectable detrimental effect on pulmonary function compared to clopidogrel.
Ticagrelor (n = 101) Clopidogrel (n = 98)
FEV1 pre beta agonist (L) 2.81 ± 0.73 2.70 ± 0.84
FEV1 post beta agonist (L) 2.74 ± 0.73 2.66 ± 0.79
FEF25-75 (%) 2.90 ± 1.26 2.62 ± 1.33
SpO2 (%) 97 ± 3 96 ± 2
TLC (L) 6.42 ± 1.28 6.27 ± 1.36
FRC (L) 3.56 ± 0.86 3.47 ± 0.94
RV (L) 2.72 ± 0.85 2.54 ± 0.89
DLCO (%) 7.00 ± 1.77 7.18 ± 2.60
Data are mean ± SD. All P values = NS for all parameters.
